News | October 23, 2024
Sumitomo Corporation entered into contract with Revorf
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Strokes are affecting approximately 1.8 million people annually
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Subscribe To Our Newsletter & Stay Updated
